EGFR and mucositis: Anti-EGFR therapy was linked with a greater frequency of skin toxicity (relative risk [RR] = 7.05; 95%CI = 2.15–23.0; p = 0.01) (Figure 8) and an increase in the incidence of severe mucositis (RR = 1.96; 95%CI = 1.58–2.00; p = 0.01) (Figure 9).